EU approves Novartis-Incyte blood cancer drug

by Bashir Adigun

Novartis AG and Incyte Corp. said Tuesday that European Union regulators approved their blood cancer drug Jakavi.

The drug is approved to reduce swelling of the spleen, one of the symptoms of the disease. The approved the drug in November and it is sold under the name Jakafi. Its generic name is ruxolitinib.

Myelofibrosis causes abnormal blood cells to build up in bone marrow, forming thick that slows the production of healthy blood cells. To make up for the shortage, other organs including the liver and the spleen begin producing blood cells. That causes swelling of the spleen. The condition also causes anemia, fatigue, and pain.

Incyte markets the drug in the U.S. and Novartis, a Swiss drug company, has the rights to market the drug in all other markets as a cancer treatment.

Incyte shares lost 13 cents to $20.16 in afternoon trading and U.S.-traded shares of Novartis slipped 6 cents to $59.32.

Shares of Incyte are down 19 percent since the company reported its second-quarter results on Aug. 2, but in total the stock is up about 60 percent since Jakafi was approved in mid-November.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Drug offers relief for symptoms of myelofibrosis

Feb 29, 2012

People with a blood cancer — myelofibrosis — can benefit from a drug called ruxolitinib, according to a randomized, double-blind, placebo-controlled clinical trial that included patients and researchers from the ...

Recommended for you

Merck completes sale of consumer unit to Bayer

9 hours ago

Drugmaker Merck said Wednesday that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 ...

Viagra ads target women for first time

Sep 30, 2014

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.

User comments